• Sangamo entered an asset purchase agreement to sell ST-920 Fabry disease gene therapy assets to PTC in a Chapter 11 Section 363 process.
• Deal value set at USD 111 million cash at closing, contingent payments up to USD 100 million tied to FDA accelerated and full approval milestones.
• Transaction requires Delaware bankruptcy court sale order; hearing scheduled for Sept. 10, 2026.
• Outside closing date set for Oct. 15, 2026, subject to specified exceptions and termination rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-374328), on August 28, 2026, and is solely responsible for the information contained therein.